Structure-based Drug Design and Pharmacokinetic Profiling of Novel Heterocyclic Androgen Receptor Inhibitors for Prostate Cancer Treatment
The utility of structure-based virtual screening combined with ADMET prediction as an effective strategy for early-stage lead identification in prostate cancer drug discovery and the improved predicted pharmacokinetic properties suggest that rational modification of heterocyclic scaffolds can yield AR antagonists with...